Kaplan-Meier curves for biochemical recurrence-free survival according to: (A) the history of DM; (B) HbA1c level.

<p>DM = diabetes mellitus, HbA1c = hemoglobin A1c</p

Patients’ characteristics.

<p>BMI = body mass index; PSA = prostatic specific antigen; DM = diabetes mellitus; HbA1c = hemoglobin A1c</p><p>Patients’ characteristics.</p

Differences in clinico-pathologic findings according to DM history and HbA1c level.

<p>DM = diabetes mellitus; HbA1c = hemoglobin A1c; PSA = prostate specific antigen; BMI = body mass index; PV = prostate volume; PSM = positive surgical margin; SVI = seminal vesicle invasion; EPE = extraprostatic extension; LNI = lymph node invasion; BCR = biochemical recurrence.</p><p>Differences in clinico-pathologic findings according to DM history and HbA1c level.</p

Multivariate regression analyses on the potential associations of preoperative diffusion-weighted imaging grading on various pathologic outcomes.

<p>Multivariate regression analyses on the potential associations of preoperative diffusion-weighted imaging grading on various pathologic outcomes.</p

The concordance rates of index lesions between diffusion-weighted imaging and prostatectomy specimen and the incidences of high grade disease according to diffusion-weighted imaging grade.

<p>The concordance rates of index lesions between diffusion-weighted imaging and prostatectomy specimen and the incidences of high grade disease according to diffusion-weighted imaging grade.</p

The examples of diffusion weighted images according to the Likert score; (A) grade III; (B) grade IV; (C) grade V.

<p>The examples of diffusion weighted images according to the Likert score; (A) grade III; (B) grade IV; (C) grade V.</p

Clinicopathologic characteristics of subjects according to the suspicion level for prostate cancer determined from diffusion weighted imaging.

<p>Clinicopathologic characteristics of subjects according to the suspicion level for prostate cancer determined from diffusion weighted imaging.</p

Characteristics of patients.

<p>BCR, biochemical recurrence; PSA, prostate specific antigen; RT, radiotherapy; PSADT, PSA doubling time; ADT, androgen deprivation therapy; RP, radical prostatectomy.</p

Multivariate analysis of parameters predicting pathologically unfavorable prostate cancer among patients in group B fulfilling each active surveillance protocol.

<p>MSKCC, Memorial Sloan-Kettering Cancer Center; PRIAS, Prostate Cancer Research International: Active Surveillance; UCSF,</p><p>University of California, San Francisco.</p><p>Multivariate analysis of parameters predicting pathologically unfavorable prostate cancer among patients in group B fulfilling each active surveillance protocol.</p

Perioperative and pathological outcomes after open partial nephrectomy and robotic partial nephrectomy among clinical T1a tumor.

<p>Perioperative and pathological outcomes after open partial nephrectomy and robotic partial nephrectomy among clinical T1a tumor.</p